DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in ...

The medical technology company reported earnings per share of $0.48, significantly surpassing the $0.45 consensus estimate. Revenue reached $1.16 billion, exceeding projections of $1.12 billion. This ...

DexCom DXCM shares soared 6.5% in the last trading session to close at $106.88. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to ...

Shares of DexCom Inc. slipped 7.66% to $75.96 Monday, on what proved to be an all-around dismal trading session for the stock ...

DexCom has enormous runway for growth in its home market, the US, and internationally. Read more to see the full investment analysis of DXCM stock.

Spanish-speaking patients can opt to use the Dexcom G6 app in their preferred language, eliminating a language barrier for optimal care.

Over the last six months, DexCom’s shares have sunk to $80.25, producing a disappointing 9.9% loss - a stark contrast to the ...

DexCom’s balance sheet looks very strong. DexCom’s Debt figure was $2.6 Bil at the end of the most recent quarter, while its market capitalization is $32 Bil (as of 5/2/2025).

Despite DexCom’s underwhelming price action, Wall Street analysts appear highly optimistic about its prospects.